Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 +2.62 (+8.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗
There are some tempting bargains if you know where to look. 
Via The Motley Fool
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Could Take Off Later This Year ↗
Some key clinical trial data is expected soon. 
Via The Motley Fool
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on"... 
Via MarketMinute
Topics ETFs Economy Stocks
News headline image
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗
One of these assets is catalyst-driven; the other isn't. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗
Each of these companies could benefit from this high-growth market over time. 
Via The Motley Fool
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Companies at the Forefront of the GLP-1 Pill Wars ↗
Via MarketBeat
News headline image
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 ↗
The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September. 
Via The Motley Fool
News headline image
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗
Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk. 
Via Stocktwits
News headline image
The Great Rotation: Russell 2000 Surges as Investors Flee Overstretched Tech Giants
NEW YORK — In a dramatic shift of market leadership, the Russell 2000 index (INDEXRUSSELL:RUT) continued its historic outperformance on Tuesday, March 10, 2026, as investors aggressively rotated... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy ETFs
News headline image
Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗
As per the CEO, the company will have four late-stage trials by the end of 2026. 
Via Stocktwits
News headline image
The $1.35 Trillion Wall: Why Small-Caps are Faltering as the S&P 500 Defies Gravity
As of March 9, 2026, the long-predicted "reckoning" for American small-cap stocks has officially arrived. While the broader market remains buoyed by the resilient "Magnificent Seven" and a robust AI... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗
This stock could make you a fortune in the next two years, or lose you a whole lot of money. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Eli Lilly has seen revenue and earnings soar in recent years. 
Via The Motley Fool
News headline image
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗
Is this the best way to cash in on the weight-loss gold rush? 
Via The Motley Fool
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Why Viking Therapeutics Stock Is Up More Than 9% Today ↗
A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow. 
Via The Motley Fool
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing... 
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated... 
Via MarketMinute
Topics Earnings
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Viking stock has plenty of room to run. 
Via The Motley Fool
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Really Going to $125? ↗
Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly. 
Via The Motley Fool
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Viking should have plenty of news to share with investors this year. 
Via The Motley Fool
News headline image
The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge
The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price... 
Via MarketMinute
Topics Bonds ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.